Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Dabrafenib”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT03919071
What this trial is testing

Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

Who this might be right for
Anaplastic AstrocytomaAnaplastic Astrocytoma, Not Otherwise SpecifiedAnaplastic Ganglioglioma+5 more
National Cancer Institute (NCI) 58
Not applicableNo Longer AvailableNCT04489433
What this trial is testing

Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma

Who this might be right for
Melanoma
Novartis Pharmaceuticals
Early research (Phase 1)Ended earlyNCT02097225
What this trial is testing

Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Who this might be right for
BRAF V600E Mutation PresentBRAF V600K Mutation PresentMetastatic Malignant Solid Neoplasm+7 more
National Cancer Institute (NCI) 22
Testing effectiveness (Phase 2)Ended earlyNCT02314143
What this trial is testing

Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib

Who this might be right for
Melanoma
GlaxoSmithKline 48
Not applicableNot Yet RecruitingNCT05988697
What this trial is testing

Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib

Who this might be right for
NSCLCBRAF V600E MutationAdvanced Cancer+2 more
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 36
Not applicableStudy completedNCT04775095
What this trial is testing

BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation

Who this might be right for
Non Small Cell Lung CancerBRAF V600 Mutation
Intergroupe Francophone de Cancerologie Thoracique 163
Testing effectiveness (Phase 2)Study completedNCT01972347
What this trial is testing

Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma

Who this might be right for
Melanoma
Melanoma Institute Australia 35
Early research (Phase 1)Study completedNCT01738451
What this trial is testing

Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors

Who this might be right for
Cancer
GlaxoSmithKline 50
Early research (Phase 1)Study completedNCT02852239
What this trial is testing

Pharmacokinetics of Dabrafenib in Subjects With Renal Impairment

Who this might be right for
Renal Impairment
Novartis Pharmaceuticals 22
Not applicableNo Longer AvailableNCT02416232
What this trial is testing

Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma

Who this might be right for
Melanoma
GlaxoSmithKline
Early research (Phase 1)WithdrawnNCT02357732
What this trial is testing

Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib

Who this might be right for
Metastatic Melanoma
University of Pittsburgh
Early research (Phase 1)Study completedNCT01231568
What this trial is testing

An Open Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation Positive Tumor

Who this might be right for
Cancer
GlaxoSmithKline 28
Early research (Phase 1)Looking for participantsNCT03975231
What this trial is testing

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

Who this might be right for
BRAF NP_004324.2:p.V600EBRAF V600K Mutation PresentThyroid Gland Anaplastic Carcinoma
City of Hope Medical Center 6
Testing effectiveness (Phase 2)Looking for participantsNCT06712875
What this trial is testing

MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas

Who this might be right for
Low Grade GliomaHigh Grade Glioma
Ann & Robert H Lurie Children's Hospital of Chicago 27
Not applicableLooking for participantsNCT05868629
What this trial is testing

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors

Who this might be right for
Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors
Novartis Pharmaceuticals 40
Early research (Phase 1)WithdrawnNCT02447939
What this trial is testing

Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma

Who this might be right for
Melanoma
GlaxoSmithKline
Not applicableStudy completedNCT07649252
What this trial is testing

Patient Characteristics and Treatment Patterns in Real-world Melanoma Patients Treated With Dabrafenib and Trametinib or Encorafenib and Binimetinib in Japan

Who this might be right for
Melanoma
Novartis Pharmaceuticals 82
Not applicableEnded earlyNCT03593993
What this trial is testing

A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent Gliomas

Who this might be right for
GliomaBRAF V600EPleomorphic Xantho-Astrocytoma+1 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 3
Not applicableStudy completedNCT06337617
What this trial is testing

A Multi-center Retrospective Study With Secondary Use of Data of Tafinlar (Dabrafenib) Plus Mekinist (Trametinib) in Chinese Patients With BRAF V600 Mutation Positive Melanoma

Who this might be right for
BRAF V600 Mutation Positive Melanoma
Novartis Pharmaceuticals 90
Large-scale testing (Phase 3)Study completedNCT01584648
What this trial is testing

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Who this might be right for
Melanoma
Novartis Pharmaceuticals 423
Next Page